secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001140361-23-039405
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant reports Q1 net loss of $327.8M, VTAMA revenue $16.7M; cash $1.45B
-------------------------------------------------------------------------

- Net loss $327.8M ($0.38/share) vs $353.8M ($0.48) YoY; non-GAAP net loss $211.5M.
- Product revenue $16.7M from VTAMA (26% gross-to-net yield); ~200K prescriptions since launch.
- Cash, equivalents, restricted cash $1.45B at June 30, down from $1.69B at March 31.
- RVT-3101 shows improved efficacy at week 56 in UC Phase 2b; TAHOE Phase 2 in Crohn's initiated.
- IMVT-1402 Phase 1 data expected Sep 2023 (SAD) and Oct/Nov 2023 (MAD); batoclimab MG data H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123039405/0001140361-23-039405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123039405/brhc20057388_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-039405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer